PubMed (MeSH Keyword) for id: 62959

Year	Number of Results
1993	2
1994	4
1995	11
1996	34
1997	46
1998	71
1999	64
2000	62
2001	45
2002	11
2003	14
2004	4
2005	7
2006	2
2007	3
2008	7
2009	10
2010	7
2011	1
2012	2
2013	4
2014	6
2015	7
2016	5
2017	1
2018	3
2019	1
2020	2
2021	1
2022	2
2023	1
2024	0

1

Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model.

Kaden T, Graf K, Rennert K, Li R, Mosig AS, Raasch M. Kaden T, et al. Sci Rep. 2023 Aug 16;13(1):13338. doi: 10.1038/s41598-023-40004-z. Sci Rep. 2023. PMID: 37587168 Free PMC article.

2

Trovafloxacin drives inflammation-associated drug-induced adverse hepatic reaction by changing macrophage polarization.

Yang H, Park T, Park D, Kang MG. Yang H, et al. Toxicol In Vitro. 2022 Aug;82:105374. doi: 10.1016/j.tiv.2022.105374. Epub 2022 May 9. Toxicol In Vitro. 2022. PMID: 35537566 Free article.

3

Identification of Trovafloxacin, Ozanimod, and Ozenoxacin as Potent c-Myc G-Quadruplex Stabilizers to Suppress c-Myc Transcription and Myeloma Growth.

Zhang J, Wang T, Geng X, Liu L, Gao J. Zhang J, et al. Mol Inform. 2022 Oct;41(10):e2200011. doi: 10.1002/minf.202200011. Epub 2022 Apr 13. Mol Inform. 2022. PMID: 35355429

4

TNFα enhances trovafloxacin-induced in vitro hepatotoxicity by inhibiting protective autophagy.

Ahn JH, Jegal H, Choi MS, Kim S, Park SM, Ahn J, Han HY, Cho HS, Yoon S, Oh JH. Ahn JH, et al. Toxicol Lett. 2021 May 15;342:73-84. doi: 10.1016/j.toxlet.2021.02.009. Epub 2021 Feb 17. Toxicol Lett. 2021. PMID: 33609687

5

Assessment of the risk of musculoskeletal adverse events associated with fluoroquinolone use in children: A meta-analysis.

Wang JG, Cui HR, Hu YS, Tang HB. Wang JG, et al. Medicine (Baltimore). 2020 Aug 21;99(34):e21860. doi: 10.1097/MD.0000000000021860. Medicine (Baltimore). 2020. PMID: 32846837 Free PMC article.

6

The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro.

Giustarini G, Huppelschoten S, Barra M, Oppelt A, Wagenaar L, Weaver RJ, Bol-Schoenmakers M, Smit JJ, van de Water B, Klingmüller U, Pieters RHH. Giustarini G, et al. Toxicol Appl Pharmacol. 2020 Mar 15;391:114915. doi: 10.1016/j.taap.2020.114915. Epub 2020 Feb 6. Toxicol Appl Pharmacol. 2020. PMID: 32035082

7

Trovafloxacin-Induced Liver Injury: Lack in Regulation of Inflammation by Inhibition of Nucleotide Release and Neutrophil Movement.

Giustarini G, Vrisekoop N, Kruijssen L, Wagenaar L, van Staveren S, van Roest M, Bleumink R, Bol-Schoenmakers M, Weaver RJ, Koenderman L, Smit J, Pieters R. Giustarini G, et al. Toxicol Sci. 2019 Feb 1;167(2):385-396. doi: 10.1093/toxsci/kfy244. Toxicol Sci. 2019. PMID: 30247740

8

When antibiotics turn toxic.

Marchant J. Marchant J. Nature. 2018 Mar 22;555(7697):431-433. doi: 10.1038/d41586-018-03267-5. Nature. 2018. PMID: 29565407 No abstract available.

9

Trovafloxacin attenuates neuroinflammation and improves outcome after traumatic brain injury in mice.

Garg C, Seo JH, Ramachandran J, Loh JM, Calderon F, Contreras JE. Garg C, et al. J Neuroinflammation. 2018 Feb 13;15(1):42. doi: 10.1186/s12974-018-1069-9. J Neuroinflammation. 2018. PMID: 29439712 Free PMC article.

10

Tissue influx of neutrophils and monocytes is delayed during development of trovafloxacin-induced tumor necrosis factor-dependent liver injury in mice.

Giustarini G, Kruijssen L, van Roest M, Bleumink R, Weaver RJ, Bol-Schoenmakers M, Smit J, Pieters R. Giustarini G, et al. J Appl Toxicol. 2018 May;38(5):753-765. doi: 10.1002/jat.3585. Epub 2018 Jan 26. J Appl Toxicol. 2018. PMID: 29377180

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

432 results

Results by year